Jincheng Pharmaceutical announced that Beijing Jincheng Taier Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received the “Drug GMP Compliance Inspection Notice” approved and issued by the Beijing Drug Administration, and the declared mirabelone API has passed the “Pharmaceutical Production Quality Management Code” compliance inspection. The inspection period is from December 11 to 15, 2023, and the scope of inspection is mirabelone raw materials. The inspection findings showed that the scope of this inspection met the requirements of the relevant regulations and appendices.

Jincheng Pharmaceutical announced that Beijing Jincheng Taier Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received the “Drug GMP Compliance Inspection Notice” approved and issued by the Beijing Drug Administration, and the declared mirabelone API has passed the “Pharmaceutical Production Quality Management Code” compliance inspection. The inspection period is from December 11 to 15, 2023, and the scope of inspection is mirabelone raw materials. The inspection findings showed that the scope of this inspection met the requirements of the relevant regulations and appendices.